nach oben

Erschienen in:

29.04.2019 | Nutrition

Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients

verfasst von: Leung Li, Stephen L. Chan, Frankie Mo, Edwin P. Hui, Jane Koh, Allen KC Chan, Nelson LS Tang, Cheuk M. Chu, Joyce Hui, Kit F. Lee, Simon Yu, Winnie Yeo

Erschienen in: Quality of Life Research | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Both Inflammation and health-related quality of life (HRQoL) are independent prognosticators in HCC patients. We hypothesized that inflammation can cause impairment in HRQoL and investigated the correlation between inflammatory status and HRQoL in HCC patients.

Methods

Clinical, laboratory and HRQoL (using EORTC QLQ-C30, QLQ-HCC18, C30 and HCC18 index-scores) data were prospectively collected from HCC patients at diagnosis. Correlation analyses were performed between HRQoL and inflammation-based markers including C-reactive protein (CRP), CRP/albumin ratio (CRP/alb), Glasgow Prognostic Score (GPS), Inflammation-Based Index (IBI) and Prognostic Index (PI).

Results

Among 445 HCC patients, higher inflammatory states were significantly correlated with worse HRQoL. For CRP and CRP/alb ratio, the HRQoL factors with higher correlations included C30 and HCC18 index-scores, certain QLQ-C30 domains and items (‘physical functioning’, ‘role functioning’, ‘fatigue’, ‘pain’, ‘appetite loss’) and QLQ-HCC18 items (‘fatigue’, ‘body image’, ‘nutrition’ and ‘abdominal swelling’), where the Pearson’s correlation coefficients were up to 0.416. Multivariate analyses indicated that worse HRQoL factors were significantly correlated with worse scores in GPS, IBI and PI.

Conclusion

In HCC patients, inflammatory status correlates with HRQoL at presentation. In particular, relatively stronger correlations with CRP-based markers have been observed in HRQoL scales that assess constitutional symptoms (QLQ-C30 ‘physical functioning’, ‘role functioning’, ‘fatigue’, ‘appetite loss’ and QLQ-HCC18 ‘fatigue’ and ‘nutrition’) and tumor burden (QLQ-C30 ‘pain’ and QLQ-HCC18 ‘abdominal swelling’ and ‘body image’). Future studies are warranted to evaluate whether intervention that reduces inflammation could improve HRQoL in HCC patients.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Kim, U. B., Doo, C. J., Baek, S. H., Kim, J. H., Lee, H. B., Park, S. K., et al. (1989). Natural history and prognostic factors of primary hepatocellular carcinoma: Study of 70 untreated patients. Korean Journal of Internal Medicine, 4(2), 136–141.CrossRefPubMed

Calvet, X., Bruix, J., Gines, P., Bru, C., Sole, M., Vilana, R., et al. (1990). Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology, 12(4 Pt 1), 753–760. https://doi.org/10.1002/hep.1840120422.CrossRefPubMed

Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P., & Patt, Y. Z. (1998). Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. American Journal of Clinical Oncology, 21(4), 386–391.CrossRefPubMed

Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., et al. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56(4), 918–928.CrossRefPubMed

Greten, T. F., Duffy, A. G., & Korangy, F. (2013). Hepatocellular carcinoma from an immunologic perspective. Clinical Cancer Research, 19(24), 6678–6685. https://doi.org/10.1158/1078-0432.ccr-13-1721.CrossRefPubMed

Yeo, W., Mo, F. K., Koh, J., Chan, A. T., Leung, T., Hui, P., et al. (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology, 17(7), 1083–1089.CrossRefPubMed

Bonnetain, F., Paoletti, X., Collette, S., Doffoel, M., Bouche, O., Raoul, J. L., et al. (2008). Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: Results from two French clinical trials. Quality of Life Research, 17(6), 831–843. https://doi.org/10.1007/s11136-008-9365-y.CrossRefPubMed

Diouf, M., Filleron, T., Barbare, J. C., Fin, L., Picard, C., Bouche, O., et al. (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. Journal of Hepatology, 58(3), 509–521.CrossRefPubMed

10.

Li, L., Mo, F. K., Chan, S. L., Hui, E. P., Tang, N. S., Koh, J., et al. (2017). Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma—clinical application of health-related quality-of-life data. BMC Cancer, 17(1), 8. https://doi.org/10.1186/s12885-016-2995-5.CrossRefPubMedPubMedCentral

11.

Li, L., & Yeo, W. (2017). Value of quality of life analysis in liver cancer: A clinician’s perspective. World Journal of Hepatology, 9(20), 867–883. https://doi.org/10.4254/wjh.v9.i20.867.CrossRefPubMedPubMedCentral

12.

Wan, S., Kuo, N., Kryczek, I., Zou, W., & Welling, T. H. (2015). Myeloid cells in hepatocellular carcinoma. Hepatology, 62(4), 1304–1312. https://doi.org/10.1002/hep.27867.CrossRefPubMedPubMedCentral

13.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRef

14.

Hernandez-Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013). Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology, 144(3), 512–527. https://doi.org/10.1053/j.gastro.2013.01.002.CrossRefPubMedPubMedCentral

15.

Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., et al. (2013). Increase in CD14 + HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunology, Immunotherapy, 62(8), 1421–1430. https://doi.org/10.1007/s00262-013-1447-1.CrossRefPubMed

16.

Rey, C., Los Arcos, M., Concha, A., Medina, A., Prieto, S., Martinez, P., et al. (2007). Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Medicine, 33(3), 477–484. https://doi.org/10.1007/s00134-006-0509-7.CrossRefPubMed

17.

Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K., et al. (2015). The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Annals of Surgical Oncology, 22(3), 803–810. https://doi.org/10.1245/s10434-014-4048-0.CrossRefPubMed

18.

Li, M. X., Bi, X. Y., Li, Z. Y., Huang, Z., Han, Y., Zhou, J. G., et al. (2015). Prognostic role of glasgow prognostic score in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore), 94(49), e2133. https://doi.org/10.1097/md.0000000000002133.CrossRef

19.

Pinato, D. J., Stebbing, J., Ishizuka, M., Khan, S. A., Wasan, H. S., North, B. V., et al. (2012). A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). Journal of Hepatology, 57(5), 1013–1020. https://doi.org/10.1016/j.jhep.2012.06.022.CrossRefPubMed

20.

Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Fushiya, N., et al. (2012). Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. British Journal of Cancer, 107(6), 988–993. https://doi.org/10.1038/bjc.2012.354.CrossRefPubMedPubMedCentral

21.

Zhou, D. S., Xu, L., Luo, Y. L., He, F. Y., Huang, J. T., Zhang, Y. J., et al. (2015). Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World Journal of Gastroenterology, 21(18), 5582–5590. https://doi.org/10.3748/wjg.v21.i18.5582.CrossRefPubMedPubMedCentral

22.

Yamamura, K., Sugimoto, H., Kanda, M., Yamada, S., Nomoto, S., Nakayama, G., et al. (2014). Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepatobiliary Pancreatic Sciences, 21(9), 682–688. https://doi.org/10.1002/jhbp.114.CrossRefPubMed

23.

Pinato, D. J., Karamanakos, G., Arizumi, T., Adjogatse, D., Kim, Y. W., Stebbing, J., et al. (2014). Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: A prospective study. Alimentary Pharmacology & Therapeutics, 40(11–12), 1270–1281. https://doi.org/10.1111/apt.12992.CrossRef

24.

Chan, S. L., Chan, A. W., Chan, A. K., Jian, P., Mo, F., Chan, C. M., et al. (2017). Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver International, 37(2), 280–289. https://doi.org/10.1111/liv.13218.CrossRefPubMed

25.

Sternby Eilard, M., Hagstrom, H., Mortensen, K. E., Wilsgaard, T., Vagnildhaug, O. M., Dajani, O., et al. (2017). Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver International. https://doi.org/10.1111/liv.13593.CrossRefPubMed

26.

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed

27.

Blazeby, J. M., Currie, E., Zee, B. C., Chie, W. C., Poon, R. T., & Garden, O. J. (2004). Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. European Journal of Cancer, 40(16), 2439–2444.CrossRefPubMed

28.

Chiba, F., Soda, K., Yamada, S., Tokutake, Y., Chohnan, S., Konishi, F., et al. (2014). The importance of tissue environment surrounding the tumor on the development of cancer cachexia. International Journal of Oncology, 44(1), 177–186. https://doi.org/10.3892/ijo.2013.2180.CrossRefPubMed

29.

Evans, W. J., Morley, J. E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., et al. (2008). Cachexia: A new definition. Clinical Nutrition, 27(6), 793–799. https://doi.org/10.1016/j.clnu.2008.06.013.CrossRefPubMed

30.

VanderVeen, B. N., Fix, D. K., & Carson, J. A. (2017). Disrupted skeletal muscle mitochondrial dynamics, mitophagy, and biogenesis during cancer Cachexia: A role for inflammation. Oxidative Medicine Cellular Longevity, 2017, 3292087. https://doi.org/10.1155/2017/3292087.CrossRefPubMed

31.

Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018). Cancer-associated cachexia. Nature Reviews Disease Primers, 4, 17105. https://doi.org/10.1038/nrdp.2017.105.CrossRefPubMed

32.

The European Organization for Research and Treatment of Cancer QLQ-C30 Questionnaire in English. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf.

33.

Chie, W. C., Yang, C. H., Hsu, C., & Yang, P. C. (2004). Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Quality of Life Research, 13(1), 257–262. https://doi.org/10.1023/b:qure.0000015295.74812.06.CrossRefPubMed

34.

Huang, C. C., Lien, H. H., Sung, Y. C., Liu, H. T., & Chie, W. C. (2007). Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22. Psychooncology, 16(10), 945–949. https://doi.org/10.1002/pon.1158.CrossRefPubMed

35.

Wan, C., Meng, Q., Yang, Z., Tu, X., Feng, C., Tang, X., et al. (2008). Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Annals of Oncology, 19(12), 2053–2060. https://doi.org/10.1093/annonc/mdn417.CrossRefPubMedPubMedCentral

36.

Zhao, H., & Kanda, K. (2000). Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Quality of Life Research, 9(2), 129–137.CrossRefPubMed

37.

Cheng, J. X., Liu, B. L., Zhang, X., Zhang, Y. Q., Lin, W., Wang, R., et al. (2011). The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Medical Research Methodology, 11, 56. https://doi.org/10.1186/1471-2288-11-56.CrossRefPubMedPubMedCentral

38.

Chie, W. C., Chang, K. J., Huang, C. S., & Kuo, W. H. (2003). Quality of life of breast cancer patients in Taiwan: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology, 12(7), 729–735. https://doi.org/10.1002/pon.727.CrossRefPubMed

39.

Chie, W. C., Hong, R. L., Lai, C. C., Ting, L. L., & Hsu, M. M. (2003). Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Quality of Life Research, 12(1), 93–98.CrossRefPubMed

40.

The European Organization for Research and Treatment of Cancer QLQ-HCC18 Questionnaire in English. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-HCC18-English.pdf.

41.

Chie, W. C., Blazeby, J. M., Hsiao, C. F., Chiu, H. C., Poon, R. T., Mikoshiba, N., et al. (2012). International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology, 55(4), 1122–1129. https://doi.org/10.1002/hep.24798.CrossRefPubMed

42.

Lachin, J. M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials, 2(2), 93–113.CrossRefPubMed

43.

Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., et al. (2010). Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: A randomized controlled trial. Annals of Oncology, 21(3), 608–614. https://doi.org/10.1093/annonc/mdp479.CrossRefPubMed

44.

Panahi, Y., Saadat, A., Beiraghdar, F., & Sahebkar, A. (2014). Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res., 28(10), 1461–1467. https://doi.org/10.1002/ptr.5149.CrossRefPubMed

Titel: Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients
verfasst von: Leung Li
Stephen L. Chan
Frankie Mo
Edwin P. Hui
Jane Koh
Allen KC Chan
Nelson LS Tang
Cheuk M. Chu
Joyce Hui
Kit F. Lee
Simon Yu
Winnie Yeo
Publikationsdatum: 29.04.2019
Verlag: Springer International Publishing
Schlagwörter: Nutrition
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Erschienen in: Quality of Life Research / Ausgabe 9/2019
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-019-02190-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Process utilities for topical treatment in atopic dermatitis

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis

Health-related quality of life in adult males with lower urinary tract symptoms

Methods for questionnaire design: a taxonomy linking procedures to test goals

Systematic review of the measurement properties of the Depression Anxiety Stress Scales–21 by applying updated COSMIN methodology

Socioeconomic inequalities in oral health-related quality of life in adolescents: a cohort study